Eclipse Bioinnovations
Dr. Peach has 30 years of drug discovery and development experience in the pharmaceutical and biotechnology industry. Robert co-founded Receptos, becoming Chief Scientific Officer and raising $59M in venture capital and $800M in an IPO. Receptos was acquired in 2015 by Celgene for $7.8B. Robert held senior executive and scientific positions in other companies including Apoptos (co-founder), Biogen Idec, IDEC Pharmaceuticals and Bristol-Myers Squibb, supporting in-licensing, acquisition and venture investments. His extensive drug discovery and development experience in autoimmune and inflammatory diseases, and cancer has resulted in multiple drugs entering clinical trials and 4 registered drugs. He currently serves on the Board of Directors of Amplia Therapeutics, AdAlta and ReKover Therapeutics, and has been a Scientific Advisory Board member and consultant for several other biotechnology companies.
This person is not in the org chart
This person is not in any offices
Eclipse Bioinnovations
Eclipse Bioinnovations Inc. is a San Diego biotechnology start-up company focused on specialized genomics technologies. Their major focus is the development of next-generation sequencing products and services to profile binding sites for RNA binding proteins, using enhanced crosslinking and immunoprecipitation (eCLIP-seq).